Bomedemstat clinical trials
Also written IMG-7289 and MK-3543.
How each study uses bomedemstat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the bomedemstat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 6
Merck Sharp & Dohme LLC (6) · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (5) · Terrence J Bradley, MD (2) · The University of Texas Health Science Center at San Antonio (1) · United Lincolnshire Hospitals NHS Trust (1) · The University of Hong Kong (1) · University of Washington (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test bomedemstat, phase 3 first.
- Jul 2027A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Phase 3 · Merck Sharp & Dohme LLC
- Sep 2027Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)Phase 3 · Merck Sharp & Dohme LLC
- Nov 2026Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPhase 1 · Terrence J Bradley, MD
Studies
Open first, then newest update. How each study uses bomedemstat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07722611Written as Bomedemstat
- A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06351631Written as Bomedemstat
- Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With MyelofibrosisNot yet recruitingPhase 2United Lincolnshire Hospitals NHS TrustNCT07424950Written as bomedemstat
- Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingPhase 1Terrence J Bradley, MDNCT05597306Written as Bomedemstat
- Bomedemstat (IMG-7289) Plus Ruxolitinib for MyelofibrosisRecruitingPhase 2The University of Hong KongNCT05569538Written as Bomedemstat
- Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2Active, not recruitingPhase 2The University of Texas Health Science Center at San AntonioNCT04081220Written as IMG-7289
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06079879Written as Bomedemstat
- Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06456346Written as Bomedemstat
- A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)CompletedPhase 2Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)NCT05558696Written as Bomedemstat
- Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)CompletedPhase 2Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)NCT04254978Written as Bomedemstat
- A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)CompletedPhase 1Merck Sharp & Dohme LLCNCT07049939Written as Bomedemstat
- IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)Active, not recruitingPhase 2Terrence J Bradley, MDNCT04262141Written as IMG-7289
- An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)CompletedPhase 2Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)NCT05223920Written as Bomedemstat
- Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)CompletedPhase 1Merck Sharp & Dohme LLCNCT06596668Written as bomedemstat
- Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung CancerTerminatedPhase 1/2University of WashingtonNCT05191797Written as Bomedemstat
- Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)CompletedPhase 1/2Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)NCT03136185Written as Bomedemstat
- A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)CompletedPhase 1/2Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)NCT02842827Written as bomedemstat
Codes
What other systems call bomedemstat · ClinicalTrials.gg INT002068
- MeSH (NLM) C000730033bomedemstatOne source ClinicalTrials.gov
- UNII (FDA) Y2T4ALDEATBOMEDEMSTATConfirmed FDA, Wikidata
- Wikidata Q118727468bomedemstatConfirmed FDA, Wikidata
- NCI Thesaurus C131827BomedemstatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000730033 | bomedemstat | One source ClinicalTrials.gov |
| UNII (FDA) | Y2T4ALDEAT | BOMEDEMSTAT | Confirmed FDA, Wikidata |
| Wikidata | Q118727468 | bomedemstat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C131827 | Bomedemstat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.